Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Obesity Drug Trials Should Be Shorter, Have Broader Endpoints, PhRMA Says

Executive Summary

The Pharmaceutical Research & Manufacturers of America is asking FDA to change its guidance on the development of weight loss drugs to allow shorter trials

You may also be interested in...



FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line

FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products

FDA Says No To Metabolic Syndrome; New Obesity Guidance Takes Hard Line

FDA currently views metabolic syndrome as "not necessarily" a distinct disease entity, according to the agency's draft guidance on obesity products

Weight-Loss Drug One-Year Data Enough For Safety and Efficacy – Cmte.

One-year trial data for weight-control drugs provides enough information to establish efficacy and safety for approval, a majority of FDA's Endocrinologic & Metabolic Drugs Advisory Committee concluded Sept. 8

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel